In non-allergic subjects, histamine induced a reduction of minimal nasal cross-sectional area (Amin) and an increase in albumin release into nasal lavage. The effect of histamine on albumin release was inhibited by pretreatment with NG-nitro-L-arginine methyl ester (L-NAME), 1 jmol but not by D-NAME, 1 jpmol.
Introduction Chemical mediators including histamine (Naclerio & Togias, 1991) , bradykinin (Proud et al., 1983) and leukotrienes (Knapp, 1990) are implicated in the pathophysiology of allergic rhinitis. These mediators are believed to be released, or synthesized, following the interaction between specific antigen and cell-bound IgE antibody. Some inflammatory mediators and neurotransmitters act on the vasculature to cause increased blood flow by stimulating the production of nitric oxide (Vallance & Collier, 1994) . Histamine is a putative mediator of seasonal allergic rhinitis because histamine HI receptor antagonists reduce some of the symptoms (Rokenes et al., 1988) . Moreover, in certain tissues, histamine induces vasodilatation by an endothelial-dependent mechanism which involves nitric oxide (NO) generation (Kelm et al., 1993) . Nitric oxide synthase is present in the human nasal mucosa (Kulkarni et al., 1994; Lundberg et al., 1995) .
Our aim was to determine the role of NO in changes in human nasal airway patency and plasma extravasation, induced by histamine or antigen.
Methods The study was approved by the local Ethics Committee and subjects gave informed consent. Ten non-allergic, healthy volunteers were used for the study of histamine provocation (20 to 52 years old) and 10 subjects with positive skin prick tests and nasal provocation tests to grass pollen were used for the study of antigen provocation (21 to 52 years old).
Minimal cross-sectional area of the nasal cavity (Amin) was determined by acoustic rhinometry as previously described (Austin & Foreman, 1994) . Plasma extravasation in the nasal airway was assessed by measuring the albumin content of nasal lavage , with a radial immunodiffusion assay (Behring Diagnostics, Milton Keynes, U.K.).
Compounds were delivered into the nasal airway in 100 pl, by means of a nasal pump spray (Perfect-Valois, U.K., Ltd). Histamine (Sigma Chemicals, Poole, Dorset, U.K.), N0-nitro-L-arginine methyl ester (Sigma Chemicals, Poole, Dorset, U.K.) and mixed grass pollen antigen (Allerayde, Nottingham, 'Author for correspondence. U.K.) were dissolved in sterile saline at concentrations of 3 mg mi7', 10 nmmol 1`or 100 mmol 1-' and 10,000 u mlrespectively.
For the histamine provocation study, a double-blind, crossover design was employed: the treatments received by each subject being selected randomly. A baseline Amin value was determined (Austin & Foreman, 1994) . Subjects were then given a nasal aerosol of either saline or L-NAME, 1 pmol to each nostril and 30 min later this was followed by provocation with histamine, 300 pg per nostril. Amin was redetermined 5 min after the histamine provocation. One week later, the cross-over study was performed. The protocol was repeated on a separate occasion with L-NAME, 10 pmol. For determination of albumin release into the nasal airway, the protocols were repeated on separate occasions: nasal lavage being substituted for acoustic rhinometry. In the nasal lavage experiments, a separate study of D-NAME, 1 pmol, was included. At least one week separated the different studies in the same subjects. The doses used and the timing of the measurements was based on pilot experiments.
For the antigen provocation study, a single-blind cross-over design was employed and the first treatment for each subject was allocated randomly. The protocol was similar to that for the histamine study except that mixed grass pollen antigen, 1000 u per nostril replaced the histamine for provocation. In addition, nasal lavage and acoustic rhinometry were determined in the same study; nasal lavage following each Amin determination.
Results Table 1 shows that histamine, 300 p.g per nostril caused a reduction in the minimal cross-sectional area of the nasal airway (Amin) and an increased leakage into the nasal airway of serum albumin. The nitric oxide synthase inhibitor., L-NAME, 1 pmol per nostril, given 30 min prior to histamine, inhibited the histamine-induced albumin leakage into the nasal airway but failed to inhibit the histamine-induced reduction of Amin. Raising the dose of L-NAME to 10 jImol failed to inhibit the histamine-induced reduction of Amin, or cause any greater inhibition of albumin release than L-NA-ME (1 JZmol). D-NAME (1 jimol) did not inhibit the histamine-induced leakage of albumin into the nasal airway. Figure 1 shows that mixed grass pollen antigen, in allergic subjects, caused a reduction of nasal airway patency (Amin) and an increase in the leakage of serum albumin into the nasal British Journal of Pharmacology (1995) 116, 1720 -1722 . 1995 Stockton Press All rights reserved 0007-1188/95 $12.00 OOA Table 1 The effect, in non-allergic subjects of NG-nitro-L-arginine methyl ester (L-NAME) on histamine-induced reduction in nasal patency (Amin) and of L-NAME and D-NAME on histamine-induced albumin release into nasal lavage <0--Antigen L-NAME Antigen L-NAME antigen antigen Figure 1 The effect of either saline or NG-nitro-L-arginine methyl ester (L-NAME) 1Imol per nostril, given 30min prior to antigen challenge (1000 u mixed grass pollens per nostril) on (a) the change in nasal patency (Amin) and (b) the change in albumin release into the nasal airway. In (a) each symbol represents a separate subject and the horizontal bars indicate the mean values which were not significantly different. Data are presented as percentage change from the baseline Amin which was 0.59+0.02cm2 for antigen and 0.52+0.04cm2 for antigen + L-NAME. In (b) the data are given as mean+ s.e.mean albumin concentrations in nasal lavage from the same 10 subjects. *Indicates a significant difference compared with antigen (P < 0.02) using a two-tailed, paired, non-parametric test.
airway. L-NAME, 1 tmol per nostril, given 30 min prior to antigen, inhibited the antigen-induced leakage of albumin into the nasal airway but failed to affect the antigen-induced reduction of Amin.
Discussion We have used L-NAME as an inhibitor of nitric oxide synthesis to evaluate the role of nitric oxide in the nasal airway responses to either histamine in non-allergic subjects or specific antigen in allergic subjects. Our data confirm that both stimuli cause nasal blockage and plasma extravasation into the nasal airway. The increase in plasma extravasation caused by histamine in non-allergic subjects or antigen in allergic subjects was inhibited by L-NAME, and in the case of histamine provocation, D-NAME was not effective. Thus, NO is involved in the pathway by which histamine or antigen challenge cause plasma extravasation. L-NAME failed to block completely both histamine-and antigen-induced plasma extravasation which may imply an NO-independent mechanism for part of this response. Nitric oxide synthase in the human nasal airway has been localized in neurones (Kulkarni et al., 1994 ) but other locations cannot be precluded. Plasma extravasation may involve both an increase in vascular permeability and an increase in blood flow; therefore, NO could be involved at either site. In other tissues (Kelm et al., 1993) , histamine-induced vasodilatation is mediated by endothelial generation of NO, so the effect of L-NAME that we observed on nasal airway plasma extravasation may result from a reduction of NO-mediated vasodilatation.
Blockage of the nasal airway can result from a number of processes including increased blood flow into cavernous venous sinusoids, increased secretion into the nasal cavity, and swelling of the mucosa resulting from plasma extravasation. We suggest that nasal blockage and increased plasma extravasation following the stimuli we employed, occur by different mechanisms: the former being independent of NO generation and the latter involving NO generation.
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